Free tool
Rare disease stocks
We cover 20 companies grouped under the Rare disease theme. The median market value in the group is $16.20B. Across the group, the median move over the past trading day is −0.13%. Price change over the past year runs from −13.8% to +198.0% across the middle 80 percent of the group, with a median of +44.8%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
20 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| VX1.DE | Vertex Pharmaceuticals Incorporated | 475.00 EUR | +10.21% | +23.55% | +41.64% | Nov 2, 2026 |
| VRTX | Vertex Pharmaceuticals Incorporated | $547.29 | +11.60% | +21.05% | +40.66% | Nov 2, 2026 |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $549.02 | +0.13% | +22.11% | +40.77% | Nov 2, 2026 |
| ARGX | argenx SE | $1,047.10 | +20.05% | +24.66% | +47.90% | Oct 22, 2026 |
| 0HD2.L | Alnylam Pharmaceuticals, Inc. | $241.82 | +0.67% | −39.23% | −46.60% | Oct 29, 2026 |
| DUL.DE | Alnylam Pharmaceuticals, Inc. | 204.00 EUR | −19.59% | −40.19% | −10.21% | Oct 29, 2026 |
| ALNY | Alnylam Pharmaceuticals, Inc. | $239.00 | −17.13% | −40.28% | −47.38% | Oct 29, 2026 |
| INSM | Insmed Incorporated | $124.39 | +19.46% | −29.77% | −7.54% | Oct 29, 2026 |
| ROIV | Roivant Sciences Ltd. | $36.75 | +8.60% | +67.58% | +206.51% | Nov 9, 2026 |
| JAZZ | Jazz Pharmaceuticals plc | $249.29 | −2.97% | +43.97% | +100.35% | Nov 4, 2026 |
| BBIO | BridgeBio Pharma, Inc. | $79.37 | −7.22% | +1.45% | +60.05% | Oct 28, 2026 |
| CORT | Corcept Therapeutics Incorporated | $119.80 | +27.19% | +213.61% | +71.81% | Nov 4, 2026 |
| 0JAV.L | Insmed Incorporated | $125.00 | +0.43% | −28.28% | −7.52% | Oct 29, 2026 |
| BMRN | BioMarin Pharmaceutical Inc. | $65.61 | +5.70% | +10.36% | +11.85% | Oct 26, 2026 |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | 52.70 EUR | +2.53% | +10.68% | +1.80% | Nov 10, 2026 |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $89.12 | +3.89% | +31.46% | +308.99% | Nov 24, 2026 |
| CYTK | Cytokinetics, Incorporated | $79.20 | −0.31% | +28.30% | +109.36% | Nov 5, 2026 |
| IONS | Ionis Pharmaceuticals, Inc. | $63.36 | +14.58% | −20.47% | +48.21% | Nov 4, 2026 |
| KYMR | Kymera Therapeutics, Inc. | $125.55 | +18.26% | +72.55% | +197.09% | Nov 3, 2026 |
| ABVX.PA | ABIVAX Société Anonyme | 102.30 EUR | −5.63% | −11.04% | +48.91% | Sep 21, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.